Eisai Co., Ltd.
↗Tokyo, Japan
Eisai Co., Ltd. is a leading global research-based pharmaceutical company headquartered in Tokyo, Japan. Founded in 1941, the company operates under the 'human health care' (hhc) philosophy, prioritizing the needs of patients and their families in its drug discovery, development, and marketing efforts.
Eisai focuses its R&D and commercial activities primarily on two core therapeutic areas: Neurology (with a strong emphasis on Alzheimer's disease and dementia) and Oncology. The company has a significant global footprint with research institutes, manufacturing sites, and marketing operations across Japan, the Americas, Europe, and Asia.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:¥789.4 billion (FY2024)
Founded:1941
Ownership:public
Status:operating
STOCK
Exchange:Tokyo Stock Exchange
Ticker:4523
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Monoclonal antibodies
Trial Phases:-
CORPORATE STRUCTURE
Subsidiaries:Eisai Inc. (USA)
Key Partnerships:Biogen (Collaboration on Alzheimer's disease treatments including LEQEMBI), BioArctic (Collaboration on Alzheimer's disease)
COMPETITION
Position:Leader
Competitors:Eli Lilly, Roche, Novartis, Merck & Co., Pfizer
LEADERSHIP
Key Executives:
Haruo Naito - CEO
LINKS
Website:eisai.net
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Eisai Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Eisai Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.